Stifel Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

Stifel Financial’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.39M	Buy	776,928 +186,780	+32%	+$722K	﹤0.01%	1837
2025 Q4	$2.41M	Buy	590,148 +147,353	+33%	+$730K	﹤0.01%	1801
2025 Q3	$2.16M	Buy	442,795 +186,703	+73%	+$980K	﹤0.01%	1854
2025 Q2	$1.3M	Buy	256,092 +68,833	+37%	+$338K	﹤0.01%	2151
2025 Q1	$991K	Buy	187,259 +27,372	+17%	+$200K	﹤0.01%	2239
2024 Q4	$1.08M	Sell	159,887 -2,091	-1%	-$14.1K	﹤0.01%	2199
2024 Q3	$1.07M	Buy	161,978 +53,103	+49%	+$381K	﹤0.01%	2186
2024 Q2	$817K	Buy	108,875 +64,466	+145%	+$562K	﹤0.01%	2309
2024 Q1	$443K	Buy	44,409 +17,220	+63%	+$192K	﹤0.01%	2688
2023 Q4	$268K	Buy	+27,189	New	+$194K	﹤0.01%	2907

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Stifel Financial's RXRX Position: Q1 2026 in Review

Stifel Financial increased its Recursion Pharmaceuticals (RXRX) stake by 32% in Q1 2026, buying an estimated $722K and bringing the position to 776,928 shares worth $2.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1837.

Stifel Financial first reported a position in RXRX in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.41M in Q4 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Stifel Financial held 776,928 shares of Recursion Pharmaceuticals worth $2.39M as of Q1 2026.
Stifel Financial bought 186,780 Recursion Pharmaceuticals shares in Q1 2026, an estimated $722K.
Recursion Pharmaceuticals made up ﹤0.01% of Stifel Financial's portfolio in Q1 2026, its #1837 holding.
Stifel Financial first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Stifel Financial's Recursion Pharmaceuticals position peaked at $2.41M in Q4 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Stifel Financial's 13F filing for Q1 2026, filed 12 May 2026.